The particulars: peptide mapping · oxidation · cagrilintide.
I am trying to choose between two options that are usually discussed as though only one exists.
I am not optimising for price, but I am not indifferent to it either.
Which axes does this decision turn on?
A useful certificate has five elements: the lot number, the analytical method, the reported result with units, the date of analysis, and the primary data or a reference to it.
Lot number visibility is the first check, and it is the one most certificates fail — the number is not printed on the vial, or it is on the certificate but the vial is unmarked.
Multiple testing on the same lot reported in a single document suggests internal quality control; identical figures across different lots suggests the same certificate reused.
Research-grade certificates carry no regulatory backing and no standing in quality systems, and that limitation is worth being explicit about.
My working rule is that a document without a lot number, a method section and a test date is marketing.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsStated carefully, the certificate is only as useful as the lot number, because without traceability it is gossip about someone else's material.
The test date matters because a certificate six months older than the vial is not evidence about your material, it is evidence about what the material was like half a year ago.
Put another way, a purity figure to two decimal places with no supporting chromatogram is giving false precision and is a red flag on the same level as spelling errors.
If the certificate does not trace to your vial, it is not evidence about your vial.
Ask whether the certificate answers the question you are actually asking, because the answer is often no.
Batch versus lot is a semantic distinction that determines whether one certificate applies to ten vials or to one, and checking this distinction is worth a minute.
A method section that differs markedly from pharmacopoeial standards is either innovative or nonstandard, and distinguishing the two requires expertise.
The standards that exist in this space — ICH Q3A, Q3B and various pharmacopoeial chapters — are worth reading once even if nothing you test is obliged to meet them.
The practical summary: check the lot number, ask for the method, and reserve judgement until you have both.
Stated carefully, the most common trap is reading a certificate as if it were a guarantee when it is actually a single point estimate from a single test.
The laboratory name and accreditation status can be checked in real time against the testing service's own register, and that two-minute check catches substituted certificates.
Be careful not to over-read this — a certificate that is imperfect is not worthless, it is just a starting point for thought rather than an endpoint.
My working rule is that a document without a lot number, a method section and a test date is marketing.
Concretely, a certificate without a method section is giving you a claim rather than a measurement, and claims are not evidence.
Test results from a material supplier are different from independent results in ways that matter for interpretation, even if both are accurate.
One qualification: a single result from a single vial at a single time is a point estimate with no error bar, and no amount of decimal places changes that.
If the certificate does not trace to your vial, it is not evidence about your vial.
edited 17 Jun 2025 by nine_point_nine — clarified the distinction between purity and content
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.